Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70

Summary

Description: The trial is designed to determine the response of the immune system of patients with breast cancer to a vaccine made from their own tumor. Researchers believe that this particular vaccine, which is made from purified heat shock proteins taken from each patient's tumor, might alert the body's immune system to recognize and attack invading cancer. To be considered potentially eligible for this study you must be a high risk breast cancer patient and have a tumor that can be removed surgically. Length/Duration: Vaccinations are administered weekly for six weeks. Follow up visits to the clinic are every three months for two years, then every six months thereafter.

Timeline

Start

2000-12

Primary completion

—

Completion

2002-10

Outcome

Outcome not reported

Stopped (Enrollment): “difficulty with accrual”

Drugs

Indications